Navigation Links
Molecular ‘On/Off Switch’ Controls Immune Defenses Against Viruss

Much like flipping a light switch, the hepatitis C virus turns on human immune defenses upon entering the body //but also turns off those defenses by manipulating interaction of key cellular proteins, UT Southwestern Medical Center researchers have found.

This same molecular “on/off switch” controls immunity against many viruses, highlighting a potential new target for novel therapeutics to fight viruses, the researchers report.

In a study available online this week and in an upcoming issue of the Proceedings of the National Academy of Sciences, UT Southwestern scientists describe how the proteins RIG-I and LGP2 normally interact to turn on and off immune response to hepatitis C.

It’s known that when a virus invades a cell, the RIG-I protein triggers the body to generate an immune response. Once the virus has been cleared out, the LGP2 protein turns off the RIG-I signals.

This interaction between RIG-I and LGP2 is vital for properly regulating immunity, but viruses such as hepatitis C can disrupt the normal process to shut down immune defenses early, the research team found.

“This knowledge will help us design drugs that mimic the viral effects on these proteins to either activate a host’s immune response or shut it down,” said Dr. Michael Gale, associate professor of microbiology and the study’s senior author. “This holds great potential in developing new disease therapies, because the tactics employed by hepatitis C to trigger immune response are similar to those employed by other viruses such as West Nile, influenza and the common cold.”

Dr. Gale’s research centers on studying the mechanisms viruses use to evade immune defenses. Of particular interest is the hepatitis C virus, a blood-borne infection transmitted by intravenous drug use, blood transfusions and sexual contact. It affects 4 million U.S. residents and is the nation’s leading cause of cirrhosis and liver cancer.

In 2005 Dr. Gale and his team completed several breakthrough studies on hepatitis C, discovering that the RIG-I protein binds to viral genetic material. Then, RIG-I changes its shape and sends signals to other proteins that spur production of interferon, a molecule that stops viral replication. The researchers also found that the virus launches a counterattack on RIG-I, producing a protein called a protease to disrupt the signaling process, preventing interferon production and allowing viral replication.

Just how RIG-I signaling is normally regulated, however, hadn’t been known.

In the current study, UT Southwestern researchers found that RIG-I and LGP2 each contain a repressor domain, a sort of docking site that controls the actions of each protein. The domain is the key site that regulates the ability of RIG-I to bind to its signaling partners, including LGP2, acting as a switch for controlling immune response, Dr. Gale said.

“Hepatitis C and others viruses hijack this signaling pathway to stop immune defenses,” he said.

His research team and others are working to design novel therapeutics and drugs that could mimic viral effects on RIG-I to spur antiviral response or, conversely, mimic viral effects on LGP2 to shut down RIG-I activity. RIG-I shutdown would be necessary in cases when the immune system’s response to a virus is dangerously overactive, which happened in many flu cases during the 1918 pandemic.

“Fine-tuning immune response to infection is where antiviral or immune regulatory drugs are headed,” said Dr. Gale.

SourceNewswise
SRM
'"/>




Related medicine news :

1. Molecular markers for early diagnosis of breast and ovarian cancer
2. Scientists Developed Map For Brain Molecular Communities
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Molecular Flaw Detected in Aggressive Breast Cancers
5. Molecular Computer Developed To perform Calculations From Within Human Body
6. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
7. Molecular Basis Of ALS Found
8. New Molecular Treatment Identified To Treat Blood Cell Cancers
9. Researchers Find Molecular "Brake" to Cell Death
10. Solitons Could Power Molecular Electronics, Artificial Muscles
11. Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... ... survivor Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer ... making the announcement, PER® president, Phil Talamo, said, “We are delighted to have ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ... Athletic Training Education program forged a relationship built upon the foundation of sports ... is consists of both student members and certified members of the Athletic Trainers’ ...
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers of high-fidelity ... electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 at the ... is the shooting, hunting and outdoor trade show and conference for the firearms, ...
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 Immune ... stage biopharmaceutical company, announced today that it will hold ... Symposium on Acute Leukemias (ISAL) XVI in ... is entitled:  "Reinforcing the Efficacy of Immunotherapy for the ... take place on Monday February 20 th , 2017 from ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... poised to potentially earn millions in revenue with the ... prevent massive numbers of strokes with a simple test ... Biotech Companies with latest developments in the markets today ... PLC (NYSE: AZN ), Cancer Genetics, Inc. ...
(Date:1/17/2017)... 2017  Maureen L. Mulvihill, President and CEO ... 6 senior sales leaders to support the nationwide ... leaders were formerly part of the top producers ... recognized for their performance, they have a proven ... relationships with key customer constituencies. "I have ...
Breaking Medicine Technology: